Acelyrin (SLRN) News Today $7.00 +0.27 (+4.01%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 23, 2024 | marketbeat.comBlair William & Co. IL Invests $936,000 in Acelyrin, Inc. (NASDAQ:SLRN)Blair William & Co. IL acquired a new stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 138,595 shares of the company's stock, valued at approximately $936,0July 20, 2024 | americanbankingnews.comContrasting Acelyrin (NASDAQ:SLRN) & UroGen Pharma (NASDAQ:URGN)July 17, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Trading Down 8.8%Acelyrin (NASDAQ:SLRN) Shares Down 8.8%July 16, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Sees Strong Trading VolumeAcelyrin (NASDAQ:SLRN) Sees Unusually-High Trading VolumeJuly 11, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Trading 9.9% Higher Acelyrin (NASDAQ:SLRN) Shares Up 9.9%July 8, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Upgraded to "Overweight" at Wells Fargo & CompanyWells Fargo & Company upgraded shares of Acelyrin from an "equal weight" rating to an "overweight" rating and set a $13.00 price objective for the company in a research note on Monday.June 10, 2024 | marketbeat.comSuperstring Capital Management LP Makes New Investment in Acelyrin, Inc. (NASDAQ:SLRN)Superstring Capital Management LP bought a new position in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 356,924 shares of the company's stock, valued at approximately $2,663,000. Acelyrin makes upJune 8, 2024 | marketbeat.comSectoral Asset Management Inc. Buys Shares of 325,549 Acelyrin, Inc. (NASDAQ:SLRN)Sectoral Asset Management Inc. purchased a new stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 325,549 shares of the company's stock, valued at approxiJune 1, 2024 | marketbeat.comAcelyrin, Inc. (NASDAQ:SLRN) Sees Significant Decline in Short InterestAcelyrin, Inc. (NASDAQ:SLRN - Get Free Report) saw a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 7,020,000 shares, a drop of 17.7% from the April 30th total of 8,530,000 shares. Currently, 11.2% of the shares of the company are short sold. Based on an average daily volume of 1,160,000 shares, the days-to-cover ratio is presently 6.1 days.May 30, 2024 | marketbeat.comDecheng Capital LLC Purchases New Position in Acelyrin, Inc. (NASDAQ:SLRN)Decheng Capital LLC purchased a new stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 1,370,951 shares of the company's stock, valued at approximately $10,227,000. Acelyrin makes upMay 29, 2024 | globenewswire.comACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024May 24, 2024 | marketbeat.comQ2 2024 EPS Estimates for Acelyrin, Inc. (NASDAQ:SLRN) Increased by HC WainwrightAcelyrin, Inc. (NASDAQ:SLRN - Free Report) - Investment analysts at HC Wainwright raised their Q2 2024 earnings per share estimates for Acelyrin in a report released on Wednesday, May 22nd. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.33) per share for thMay 22, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) PT Raised to $18.00HC Wainwright boosted their price objective on shares of Acelyrin from $16.00 to $18.00 and gave the stock a "buy" rating in a research note on Wednesday.May 18, 2024 | finance.yahoo.comAcelyrin, Inc. (SLRN)May 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for ACELYRIN, INC. on Solid Financials and Promising PipelineMay 15, 2024 | investorplace.comSLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024May 15, 2024 | markets.businessinsider.comACELYRIN, INC.: Strong Buy Recommendation on Promising Izo Drug Prospects and Strategic AdvancementsMay 9, 2024 | marketwatch.comAcelyrin Founder Steps Down as CEOMay 9, 2024 | msn.comAcelyrin names Mina Kim as new Chief Executive OfficerMay 9, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Price Target Cut to $18.00HC Wainwright dropped their price objective on Acelyrin from $28.00 to $18.00 and set a "buy" rating for the company in a report on Thursday.May 9, 2024 | finance.yahoo.comACELYRIN, INC. Announces Leadership TransitionMay 9, 2024 | globenewswire.comACELYRIN, INC. Provides Business Update and Highlights Key Upcoming MilestonesMay 6, 2024 | marketbeat.comAcelyrin (SLRN) to Release Earnings on MondayAcelyrin (NASDAQ:SLRN) will be releasing earnings after the market closes on Monday, May 13, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=591359)April 29, 2024 | globenewswire.comACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024April 19, 2024 | marketbeat.comVontobel Holding Ltd. Purchases Shares of 325,549 Acelyrin, Inc. (NASDAQ:SLRN)Vontobel Holding Ltd. acquired a new position in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 325,549 shares of the company's stock, valued at approximately $2,429,000. Vontobel Holding Ltd. owned about 0.3April 17, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Hits New 12-Month Low at $5.10Acelyrin (NASDAQ:SLRN) Sets New 1-Year Low at $5.10April 16, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Shares Down 5.1% Acelyrin (NASDAQ:SLRN) Trading Down 5.1%April 14, 2024 | marketbeat.comAcelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Acelyrin, Inc. (NASDAQ:SLRN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven research firms that are covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and four have given a buyApril 10, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Hits New 12-Month Low at $5.61Acelyrin (NASDAQ:SLRN) Sets New 12-Month Low at $5.61April 3, 2024 | marketbeat.comAcelyrin, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.82) Per Share (NASDAQ:SLRN)Acelyrin, Inc. (NASDAQ:SLRN - Free Report) - Research analysts at HC Wainwright issued their Q2 2024 EPS estimates for shares of Acelyrin in a research report issued on Monday, April 1st. HC Wainwright analyst E. Bodnar expects that the company will earn ($0.82) per share for the quarter. HC WainApril 2, 2024 | marketbeat.comResearch Analysts Issue Forecasts for Acelyrin, Inc.'s Q1 2024 Earnings (NASDAQ:SLRN)Acelyrin, Inc. (NASDAQ:SLRN - Free Report) - HC Wainwright issued their Q1 2024 EPS estimates for shares of Acelyrin in a report issued on Monday, April 1st. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($0.86) per share for the quarter. HC Wainwright currentlyApril 1, 2024 | msn.comStocks Pressured as Bond Yields Jump on Strength in US ManufacturingApril 1, 2024 | markets.businessinsider.comACELYRIN, INC.: Promising Clinical Trials and Market Opportunity Justify Buy RatingApril 1, 2024 | marketbeat.comAcelyrin's (SLRN) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $28.00 target price on shares of Acelyrin in a research note on Monday.March 28, 2024 | investorplace.comSLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023March 28, 2024 | finance.yahoo.comACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent HighlightsMarch 28, 2024 | globenewswire.comACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent HighlightsMarch 21, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Shares Down 6.3% Acelyrin (NASDAQ:SLRN) Stock Price Down 6.3%March 21, 2024 | marketbeat.comWells Fargo & Company Raises Acelyrin (NASDAQ:SLRN) Price Target to $13.00Wells Fargo & Company raised their price objective on shares of Acelyrin from $11.00 to $13.00 and gave the stock an "equal weight" rating in a report on Thursday.March 20, 2024 | markets.businessinsider.comBuy Rating on ACELYRIN, INC.: Promising Clinical Prospects for Novel TED Therapy LonigutamabMarch 20, 2024 | markets.businessinsider.comAcelyrin Announces Positive Phase 1/2 Data For Lonigutamab In Thyroid Eye Disease; Stock UpMarch 20, 2024 | msn.comInvestors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease PatientsMarch 20, 2024 | finance.yahoo.comACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye DiseaseMarch 20, 2024 | marketbeat.comAcelyrin, Inc. (NASDAQ:SLRN) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Acelyrin, Inc. (NASDAQ:SLRN - Get Free Report) have earned an average rating of "Moderate Buy" from the seven research firms that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendatMarch 20, 2024 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Acelyrin (NASDAQ:SLRN)HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Acelyrin in a research report on Wednesday.March 18, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Shares Gap Down to $7.84Acelyrin (NASDAQ:SLRN) Shares Gap Down to $7.84March 18, 2024 | finance.yahoo.comSLRN Apr 2024 2.500 putMarch 15, 2024 | marketbeat.comWalleye Capital LLC Acquires New Stake in Acelyrin, Inc. (NASDAQ:SLRN)Walleye Capital LLC acquired a new stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 447,355 shares of the company's stock, valued at approximately $4,550,000. Walleye Capital LLC owned approximately 0March 12, 2024 | seekingalpha.comAcelyrin: Analyzing Its Recovery And Potential In Psoriatic ArthritisMarch 12, 2024 | markets.businessinsider.comHold Rating Affirmed for ACELYRIN, INC. as Izokibep Faces Competitive Hurdles and Safety Concerns Get Acelyrin News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Get out of cash before the Fed's next meeting (Ad)"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains." Click here now to watch this exclusive interview SLRN Media Mentions By Week SLRN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLRN News Sentiment▼0.650.62▲Average Medical News Sentiment SLRN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLRN Articles This Week▼23▲SLRN Articles Average Week Get Acelyrin News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AMRX News MRVI News JANX News DCPH News PTGX News RCKT News CPRX News ARVN News SNDX News EWTX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLRN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acelyrin, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acelyrin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.